Day One Biopharmaceuticals Inc

NASDAQ DAWN

Download Data

Day One Biopharmaceuticals Inc Working Capital Turnover Ratio 1 year YoY Change (%) for the quarter ending September 19, 2024

Day One Biopharmaceuticals Inc Working Capital Turnover Ratio 1 year YoY Change (%) is NA for the quarter ending September 19, 2024. The working capital turnover ratio measures the efficiency of a company in utilizing its working capital to generate revenue. It is calculated by dividing the revenue by the working capital. This ratio indicates the number of times the company's working capital is converted into revenue during a specific period. A higher working capital turnover ratio suggests more efficient utilization of working capital in revenue generation. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Day One Biopharmaceuticals Inc Working Capital Turnover Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Day One Biopharmaceuticals Inc Working Capital Turnover Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Day One Biopharmaceuticals Inc Working Capital Turnover Ratio for the quarter ending March 31, 2021 was 0.00.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email